Loading...
Loading...
ONVO| Name | Value |
|---|---|
| Revenues | 5.0K |
| Cost of Revenue | 72.0K |
| Gross Profit | -67.0K |
| Operating Expense | 3,685.0K |
| Operating I/L | -3,680.0K |
| Other Income/Expense | 76.0K |
| Interest Income | 76.0K |
| Pretax | -3,604.0K |
| Income Tax Expense | -72.0K |
| Net Income/Loss | -3,604.0K |
Organovo Holdings, Inc. is a biotechnology company specializing in developing 3D human tissues using its proprietary NovoGen Bioprinters and related technologies. These 3D tissues, such as ExVive human liver and kidney tissues, are utilized for predictive preclinical testing of drug compounds. The company generates revenue by offering its 3D tissue platform and related products to pharmaceutical and biotechnology companies for drug development and testing purposes.
